# OnCo record multidisciplinary-tumour-board (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/multidisciplinary-tumour-board/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "multidisciplinary-tumour-board" ;
  schema:name "Multidisciplinary tumour boards"@en ;
  schema:description "Multidisciplinary tumour boards are regular meetings where surgeons, oncologists, radiologists and pathologists review each patient's case with the full dataset and agree a plan before treatment starts. They are mandatory in the UK and for accreditation in the US, Europe and Germany, and change the diagnosis or plan in 10 to 30% of cases, though randomised evidence is lacking."@en ;
  schema:url <https://onco.cc/technologies/multidisciplinary-tumour-board/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Tumor_board> ;
  schema:citation <https://doi.org/10.1136/bmj.c951>, <https://doi.org/10.1200/po.20.00495>, <https://www.macmillan.org.uk/cancer-information-and-support/bowel-cancer/multidisciplinary-team-for-bowel-cancer>, <https://www.nice.org.uk/guidance/ng151/chapter/Recommendations>, <https://www.nice.org.uk/guidance/ng122/chapter/Management>, <https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/your-medical-team-mdt>, <https://www.nice.org.uk/guidance/ng47> ;
  onco:status "standard-of-care" ;
  onco:tag "gap-fill" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/malt-lymphoma/>, <https://onco.cc/cancers/splenic-marginal-zone-lymphoma/>, <https://onco.cc/cancers/nodal-marginal-zone-lymphoma/>, <https://onco.cc/cancers/waldenstrom/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/>, <https://onco.cc/cancers/burkitt-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/>, <https://onco.cc/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/angioimmunoblastic-t-cell-lymphoma/>, <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/>, <https://onco.cc/cancers/sezary-syndrome/>, <https://onco.cc/cancers/primary-cns-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/digital-pathology-ai/>, <https://onco.cc/technologies/telehealth-oncology/> ;
  onco:companies <https://onco.cc/companies/palitra-bio/>, <https://onco.cc/companies/pathfinder-oncology/>, <https://onco.cc/companies/private-health-management/>, <https://onco.cc/companies/private-medical/> ;
  onco:terms <https://onco.cc/terms/standard-of-care/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-taylor-bmj/>, <https://onco.cc/key-papers/paper-larson-jco-precis-oncol/> .